Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11625535 | 0.75 | ALDH1A1 (0.76) | NPSR1HTTMMP13SORT1TSHR | |
| SCHEMBL5639502 | 0.73 | RECQL (0.53) | NPSR1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL3459320 | 0.73 | NPSR1 (0.58) | NPSR1HTTMMP13TSHRALDH1A1 | |
| SCHEMBL30565166 | 0.73 | NPSR1 (0.58) | NPSR1HTTMMP13TSHRALDH1A1 | |
| SCHEMBL15421497 | 0.73 | NAMPT (0.62) | NPSR1HTTMMP13TSHRALDH1A1 | |
| SCHEMBL7663247 | 0.72 | RECQL (0.64) | NPSR1HTTALDH1A1MAPTLMNA | |
| SCHEMBL26719552 | 0.72 | ALDH1A1 (0.40) | NPSR1HTTALDH1A1MAPTGAA | |
| SCHEMBL29367205 | 0.71 | HTT (0.69) | NPSR1HTTMMP13TSHRALDH1A1 | |
| SCHEMBL2229698 | 0.71 | HDAC1 (0.72) | NPSR1HTTMMP13SORT1TSHR | |
| SCHEMBL11626058 | 0.71 | VNN1 (0.67) | NPSR1HTTSORT1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | claimed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | claimed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | NPSR1 3424/4885HTT 929/4885MMP13 1231/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | NPSR1 3754/4885HTT 2592/4885MMP13 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.